Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × durvalumab × 30 days × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 23 Lung Neoplasms 17 Small Cell Lung Carcinoma 9 Urinary Bladder Neoplasms 7 Carcinoma, Hepatocellular 7 Neoplasms 6 Liver Neoplasms 5 Cholangiocarcinoma 5 Biliary Tract Neoplasms 5 Neoplasms by Site 3 Triple Negative Breast Neoplasms 2 Thoracic Neoplasms 2 Stomach Neoplasms 2 Respiratory Tract Neoplasms 2 Respiratory Tract Diseases 2 Pathologic Complete Response 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Lung Diseases 2 Gallbladder Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Bronchogenic 2 Carcinoma 2 Bronchial Neoplasms 2 Breast Neoplasms 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡